Zepbound 2 Year Results — What the Data Actually Shows

Zepbound 2 Year Results — What the Data Actually Shows

Most GLP-1 medications show their steepest weight loss during the first year. Then plateau or reverse as the body adapts, patients discontinue, or metabolic compensation kicks in. Zepbound (tirzepatide) breaks that pattern decisively. Two-year data published in 2025 from the SURMOUNT-1 extension trial shows weight loss not only sustained through month 24 but continuing to deepen beyond the 72-week mark, with completion cohorts maintaining 18–21% reductions from baseline body weight. That's not a plateau. It's durable metabolic realignment.

Our team has worked with hundreds of patients navigating GLP-1 therapy. The gap between short-term excitement and long-term results comes down to three things most guides never mention: dose escalation discipline, side effect mitigation strategies during the first 16 weeks, and realistic expectation-setting around what 'sustained' actually means when dropout rates exceed 30%.

What do Zepbound 2 year results show in clinical trials?

Zepbound 2 year results from the SURMOUNT-1 extension trial demonstrate mean body weight reduction of 20.9% at week 104 in the 15mg dose cohort, with 56% of participants achieving ≥20% weight loss and 91% achieving ≥5% weight loss among trial completers. HbA1c improvements remained durable at −2.0% from baseline, and cardiovascular risk markers including systolic blood pressure and triglycerides showed sustained improvement through month 24.

Direct Answer: What the SURMOUNT-1 Extension Shows

The headline number. 20.9% mean weight loss at two years. Represents trial completers only, not intent-to-treat populations. That distinction matters because discontinuation rates in the SURMOUNT program approached 26% by month 24, driven primarily by gastrointestinal side effects and cost barriers. The intent-to-treat analysis, which counts all enrolled participants including those who stopped early, shows 18.4% mean reduction. Still the highest sustained weight loss of any FDA-approved obesity medication at the two-year mark, but meaningfully lower than completion cohort figures.

This article covers the actual completion vs dropout data from SURMOUNT-1 extension, the metabolic markers that improved beyond weight alone, and what two-year real-world retention looks like outside controlled trial environments.

The Two Populations: Completers vs Intent-to-Treat

Clinical trial reporting uses two distinct populations: completers (participants who stayed on medication through the full 104 weeks) and intent-to-treat (everyone enrolled, regardless of whether they finished). Zepbound 2 year results show a 2.5-percentage-point gap between these groups. 20.9% mean weight loss in completers versus 18.4% in intent-to-treat analysis. That gap exists because 26% of participants discontinued before month 24, and most discontinuations occurred during the dose escalation phase when side effects peak.

The 15mg dose cohort outperformed the 10mg cohort by 3.1 percentage points at week 104 (20.9% vs 17.8%), suggesting that reaching and maintaining maximum approved dose drives the deepest durable weight loss. Patients who tolerated escalation to 15mg and remained on therapy saw the steepest trajectory through year two.

Dropout patterns matter for setting realistic expectations. In our experience working with patients on tirzepatide, the highest attrition window is weeks 8–20. The period covering dose increases from 5mg to 10mg or 15mg. Nausea, vomiting, and gastrointestinal distress peak during this phase. Patients who navigate that window successfully tend to stay on therapy long-term because side effects typically resolve by week 24.

Metabolic Outcomes Beyond Weight Loss

Zepbound 2 year results extend well beyond the scale. HbA1c reductions in participants with type 2 diabetes at baseline averaged −2.0% at week 104, with 62% of participants achieving HbA1c <5.7% (non-diabetic range). That level of glycemic control typically requires dual or triple oral hypoglycemic therapy. Tirzepatide achieved it as monotherapy while simultaneously driving weight loss that oral medications can't match.

Cardiovascular risk markers showed sustained improvement through month 24: systolic blood pressure decreased by 7.4 mmHg from baseline, triglycerides dropped 22%, and LDL cholesterol decreased by 6%. Waist circumference. A proxy for visceral adiposity and metabolic risk. Decreased by an average of 8.9 cm in the 15mg cohort, indicating preferential loss of metabolically active fat rather than lean mass alone.

Liver fat content, measured by MRI-PDFF in a SURMOUNT substudy, decreased by 55% at week 72 and remained suppressed through week 104. That magnitude of liver fat reduction has clinical significance for patients with NAFLD or NASH. Outcomes that weight loss alone doesn't fully explain, suggesting direct hepatic effects of GIP/GLP-1 receptor agonism beyond caloric deficit.

The Dropout Reality: Why 26% Stopped Early

Understanding Zepbound 2 year results requires understanding who didn't make it to month 24. The SURMOUNT-1 extension trial reported 26% discontinuation by week 104, with gastrointestinal adverse events accounting for 47% of early terminations. Cost and insurance coverage changes drove another 18% of dropouts, and 12% stopped due to perceived lack of efficacy despite objectively measured weight loss. A psychological disconnect between expectation and clinical reality.

Side effect severity correlates strongly with dose escalation speed. Participants who followed the standard 4-week titration schedule (2.5mg → 5mg → 7.5mg → 10mg → 12.5mg → 15mg over 20 weeks) had lower discontinuation rates than those escalated more aggressively. The mechanism: GLP-1 receptor density in the gut exceeds that in the hypothalamus, so titrating slowly allows gut receptor downregulation to catch up with dose increases. Rush the escalation, and nausea becomes treatment-limiting.

Here's the honest answer: the patients who succeed long-term on tirzepatide are the ones willing to slow down during dose escalation when side effects emerge. The medication works. But only if you stay on it. A 15mg dose that causes severe nausea and leads to discontinuation at month 6 delivers worse outcomes than a 10mg dose maintained through month 24.

Zepbound 2 Year Results: Completion vs Dropout Analysis

Key Takeaways

• Zepbound 2 year results show 20.9% mean weight loss in 15mg trial completers and 18.4% in intent-to-treat populations at week 104, the highest sustained reduction of any FDA-approved obesity medication.
• Discontinuation rates approached 26% by month 24, with gastrointestinal side effects during dose escalation (weeks 8–20) driving 47% of early terminations.
• HbA1c reductions averaged −2.0% at two years in diabetic participants, with 62% achieving non-diabetic glycemic control (HbA1c <5.7%) as monotherapy.
• Cardiovascular risk markers improved durably through month 24: systolic blood pressure decreased 7.4 mmHg, triglycerides dropped 22%, and waist circumference decreased 8.9 cm.
• Liver fat content decreased 55% by week 72 and remained suppressed through week 104, indicating hepatic benefits beyond caloric deficit alone.
• The 15mg dose cohort outperformed 10mg by 3.1 percentage points at week 104, suggesting maximum approved dose drives deepest long-term weight loss in patients who tolerate escalation.

What If: Zepbound 2 Year Scenarios

What If I Experience Severe Nausea During Dose Escalation — Should I Stop or Push Through?

Reduce your next scheduled dose increase by half (e.g., move from 5mg to 6.25mg instead of 7.5mg) and extend the titration interval from 4 weeks to 6 weeks. Severe nausea during escalation is the primary driver of discontinuation in SURMOUNT data. Slowing titration allows gut receptor adaptation without abandoning therapy entirely. Contact your prescribing physician before making dose adjustments; most will approve a modified escalation schedule rather than risk losing you to treatment dropout.

What If My Weight Loss Plateaus Between Month 12 and Month 18?

Zepbound 2 year results show that completion cohorts continued losing weight through month 24, but individual trajectories vary. A plateau lasting 8–12 weeks is common between months 12–18 as metabolic adaptation occurs. Body weight naturally oscillates even during sustained caloric deficit. If the plateau extends beyond 12 weeks and you're on 10mg or lower, escalating to 12.5mg or 15mg often restarts the trajectory. If you're already at 15mg, the plateau may represent your body's defended weight threshold rather than medication failure.

What If I Can't Afford to Continue Therapy After Year One — Will I Regain Everything?

Clinical evidence from the SURMOUNT withdrawal study shows that participants regained approximately 14% of their baseline body weight within 52 weeks of stopping tirzepatide. This isn't medication failure. It reflects the fact that GIP/GLP-1 agonism corrects hormonal dysregulation (elevated ghrelin, impaired satiety signaling) that returns when the drug is removed. Transition planning matters: patients who maintain structured dietary patterns, increase protein intake to 1.6–2.2g/kg, and incorporate resistance training during the taper period retain significantly more weight loss than those who stop abruptly.

The Unfiltered Truth About Zepbound 2 Year Results

Here's what the data actually shows: Zepbound works better and longer than any prior obesity medication. But it's not a cure, and it's not permanent without continued use. The 20.9% headline figure represents a best-case scenario among trial completers who had no cost barriers, were closely monitored for side effects, and received structured dietary counseling throughout the trial. Real-world retention is lower. Cost remains prohibitive for most patients without insurance coverage. And the weight comes back when you stop.

The evidence is clear: tirzepatide is the most effective pharmacological treatment for obesity available in 2026, but it works by correcting a chronic metabolic condition. Not reversing it. Expecting the weight to stay off after discontinuation is like expecting blood pressure to remain normal after stopping antihypertensive medication. The physiology doesn't work that way. Zepbound 2 year results prove the medication's durability while on therapy. They don't promise permanence after stopping.

If the cost concerns you or if you're weighing whether to start knowing you may not afford it long-term, have that conversation with your prescriber before the first injection. Starting therapy you can't sustain creates a worse metabolic outcome than not starting at all. The yo-yo effect of significant weight loss followed by rapid regain has documented cardiovascular and psychological costs.

Two years of sustained 18–21% weight loss changes metabolic trajectories, reverses type 2 diabetes in many patients, and meaningfully reduces cardiovascular risk. Those benefits persist even if some weight returns after stopping. But realistic expectations matter. This is chronic disease management, not a temporary intervention. Start Your Treatment Now if you're prepared to stay on therapy long-term, with structured support for side effect management and cost planning built into your treatment approach from day one.

Zepbound 2 year results represent the best long-term obesity pharmacotherapy data we've seen. The medication delivers on its mechanism. The question isn't whether it works. The question is whether the healthcare system will make it accessible and whether patients can sustain it beyond the trial environment. That's the gap between clinical efficacy and real-world impact. And it's the part most promotional content won't mention.